Premium
Eltenac, a new anti‐inflammatory and analgesic drug for horses: clinical aspects
Author(s) -
PRÜGNER W.,
HUBER R.,
LÜHMANN R.
Publication year - 1991
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1991.tb00822.x
Subject(s) - medicine , placebo , analgesic , horse , lameness , anesthesia , etodolac , clinical trial , surgery , paleontology , alternative medicine , pathology , biology
Two controlled studies to determine efficacy in the horse were performed with eltenac, a new injectable, non‐steroidal anti‐inflammatory drug (NSAID). Clinical trials were carried out with a dose rate of 1 mg/kg body weight in a randomized, placebo‐controlled, double‐blind design to assess therapeutic efficacy in acute inflammatory disorders and in animals with orthopaedic conditions. In a preliminary pharmacokinetic investigation in six horses mean elimination half‐life was 1.7 h after i.v. administration. In the first clinical study, analgesic activity on pain‐related lameness was determined in a total of 64 horses. Pain was assessed using a rating scale. Compared with the placebo treatment, eltenac produced significant pain relief after a single i.v. injection for a period of 24 h. In the second trial the anti‐oedematous effect was determined in post‐operative wound swelling following castration in two groups of 10 colts. After surgery, the horses received either an injection of 1 mg/kg eltenac or a placebo injection on three consecutive days. Swelling was assessed by measuring the diameter of the external preputial fold using two methods: callipers and a rating scale of 0 to 3. Additionally, photographs were taken on days 1, 2 and 4. Compared with the placebo treatment, eltenac inhibited pain and swelling significantly. The effect was maintained for up to 48 h after the last injection.